Abstract
Summary The results of growth delay studies in ten xenograft lines of colo-rectal carcinoma are in broad agreement with clinical experience. The average response corresponded to a delay of only 0.5 tumour volume doubling time. If a response is arbitrarily scored as being equivalent to one or more tumour doubling times a response was observed in only 14 of 64 (21%) single drug studies. In four patients where a comparison of clinical and xenograft response could be attempted there was some evidence for agreement. Melphalan, 5-fluorouracil and hexamethylmelamine were the most effective single agents and it is suggested that melphalan and hexamethylmelamine merit further clinical evaluation. So far as pancreatic carcinoma is concerned no clinical-xenograft correlations are available, but a range of commonly used drugs appeared to be inactive in the system tested. These observations are being examined in a wider range of pancreatic carcinoma xenografts.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
